Fluorescite

Dosage for Fluorescein depends entirely on the method of administration and the diagnostic goal.

• Intravenous Angiography: The standard adult dose is 500 mg. This is typically administered as a rapid bolus injection into the antecubital vein (the vein in the crook of the arm). Depending on the concentration provided by the pharmacy, this may be 5 mL of a 10% solution or 2 mL of a 25% solution. In some clinical settings, a lower dose (250 mg) may be used if the patient is highly sensitive or if high-speed digital imaging is available.
• Topical Application (Drops): For routine eye exams or pressure measurements, 1 to 2 drops of a 0.25% to 2% solution are instilled into the conjunctival sac (the space between the eyelid and the eye).
• Topical Application (Strips): One strip is moistened with a sterile solution and applied to the inner surface of the lower eyelid. The patient is then asked to blink to distribute the dye.

Fluorescein is approved for use in pediatric populations, though dosing must be carefully calculated based on body weight.

• Intravenous Angiography: The standard pediatric dose is 7.7 mg per kilogram of body weight (3.5 mg/lb). For example, a child weighing 20 kg would receive 154 mg of Fluorescein. The maximum dose should not exceed the standard adult dose of 500 mg.
• Topical Application: Pediatric use for topical exams follows the same protocol as adults (1 drop or 1 strip application). There are no specific age-related restrictions for topical use, though cooperation from the child is necessary for an accurate exam.

Renal Impairment

Since Fluorescein is primarily excreted by the kidneys, patients with renal insufficiency (kidney disease) may experience prolonged retention of the dye. While specific dose-reduction formulas are not standardized in the FDA labeling, healthcare providers often use a reduced dose (e.g., 250 mg instead of 500 mg) for patients with a GFR (Glomerular Filtration Rate) below 30 mL/min. In patients on dialysis, the dye is cleared slowly, and urine discoloration may persist for several days.

Hepatic Impairment

Because the liver is responsible for the glucuronidation of Fluorescein, patients with severe liver failure or cirrhosis may have altered metabolism. However, no specific dosage adjustments are mandated. Providers should monitor these patients closely for signs of toxicity, although systemic toxicity is rare.

Elderly Patients

No specific dosage adjustments are required for elderly patients based on age alone. However, since older adults are more likely to have reduced renal function or underlying cardiovascular disease, the lowest effective dose for angiography is often preferred.

Fluorescein is administered exclusively by trained healthcare professionals in a clinical or hospital setting.

• Intravenous Administration: You will be seated in front of a specialized camera (fundus camera). A nurse or technician will insert a small needle or catheter into a vein in your arm. The dye is injected quickly. You may feel a warm sensation or a metallic taste in your mouth; this is normal and usually lasts only a few seconds.
• Topical Administration: You will be asked to tilt your head back and look upward. The provider will place a drop or a strip in your eye. You should avoid rubbing your eyes for several minutes after application to prevent corneal scratches while the eye is potentially numb (if an anesthetic was used).
• Storage: Fluorescein solutions should be stored at room temperature (15°C to 30°C) and protected from strong light. Multi-dose bottles must be discarded according to facility policy to prevent bacterial contamination.

Since Fluorescein is a diagnostic agent used during a scheduled medical procedure, 'missing a dose' in the traditional sense does not occur. If a procedure is cancelled or the injection is not completed, your doctor will simply reschedule the exam. There is no need for 'make-up' doses.

Systemic overdose of Fluorescein is extremely rare because the dose is strictly controlled by the administering clinician. In the event of an accidental overdose, symptoms may include severe nausea, vomiting, or a generalized yellowing of the skin and eyes that lasts longer than usual. Treatment is supportive, focusing on hydration to help the kidneys flush the dye from the system. In cases of severe allergic reactions (which are not necessarily dose-dependent), emergency medical intervention with epinephrine and antihistamines is required.

> Important: Always follow your healthcare provider's instructions regarding preparation for your eye exam. Do not attempt to use Fluorescein products at home.

Most patients receiving Fluorescein will experience some degree of the following expected effects. These are considered pharmacological properties of the dye rather than adverse reactions:

• Skin Discoloration: Because the dye distributes through the capillaries, your skin may take on a yellowish or slightly jaundiced hue for 6 to 12 hours after an intravenous injection. This is most noticeable in patients with lighter skin tones.
• Urine Discoloration: This is the most common effect. Your urine will appear bright yellow, orange, or even 'neon' green for 24 to 48 hours following the procedure. This is harmless and simply indicates the kidneys are excreting the dye.
• Nausea: Approximately 5% to 10% of patients experience brief nausea immediately following the IV injection. This usually passes within 1 to 2 minutes without treatment.
• Visual Blurring: Following topical application or during the bright flashes of angiography, your vision may be temporarily blurred or you may see 'spots' (after-images).

• Vomiting: Some patients may experience a single episode of vomiting shortly after the injection.
• Gastrointestinal Upset: Abdominal cramping or a 'queasy' stomach may persist for an hour or two.
• Pruritus (Itching): A mild, localized itching at the injection site or a generalized itchy feeling without a rash.
• Extravasation Pain: If the dye leaks out of the vein during injection (extravasation), it can cause significant local pain, burning, and skin staining.

• Syncope (Fainting): A vasovagal response to the needle or the procedure itself.
• Urticaria (Hives): A mild allergic reaction characterized by red, itchy welts on the skin.
• Pyrexia (Fever): A transient rise in body temperature shortly after administration.
• Dysgeusia: A metallic or bitter taste in the mouth during the injection.

While rare, Fluorescein can cause life-threatening reactions. You must alert your medical team immediately if you experience:

• Anaphylaxis: This is a severe allergic reaction. Symptoms include swelling of the lips, tongue, or throat, difficulty breathing, a rapid drop in blood pressure, and a feeling of impending doom.
• Bronchospasm: Wheezing or intense chest tightness, particularly in patients with a history of asthma.
• Cardiac Arrest: Sudden loss of heart function. While extremely rare, this has been reported following Fluorescein injection.
• Seizures: Uncontrolled electrical activity in the brain, which may manifest as shaking or loss of consciousness.
• Angioedema: Deep swelling under the skin, especially around the eyes or mouth.

> Warning: Stop the procedure and call for emergency help immediately if you feel your throat closing or if you begin to wheeze after the injection.

Fluorescein is a 'one-and-done' diagnostic agent. It does not accumulate in the body with repeated use (if spaced appropriately), and there are no known long-term side effects such as organ damage or carcinogenicity. However, repeated injections in patients with severe kidney disease should be monitored to ensure the dye is clearing between sessions.

Fluorescein sodium does not currently carry an FDA Black Box Warning. However, the FDA-approved labeling contains prominent warnings regarding the risk of severe adverse reactions, including death, due to anaphylaxis. This is why the drug must only be administered in settings where emergency resuscitation equipment (including oxygen, epinephrine, and a defibrillator) is immediately available.

Report any unusual symptoms or persistent skin changes to your healthcare provider. Even if a symptom seems minor, it is important for your medical record.

Fluorescein is generally safe, but its use requires strict medical supervision. The most critical safety point is the risk of hypersensitivity. Even if you have had a Fluorescein injection in the past without issues, you can still develop an allergic reaction during a subsequent test. Patients must remain under observation for at least 30 to 60 minutes following an intravenous injection to monitor for delayed reactions.

No FDA black box warnings for Fluorescein. However, the standard 'Precautions' section of the label is treated with the same level of clinical gravity as a black box warning regarding anaphylaxis.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern with systemic Fluorescein. Patients with a history of multiple allergies, hay fever, or eczema are at a slightly higher risk. A 'test dose' is generally not recommended because a negative test dose does not guarantee that the full dose won't cause a reaction, and the test dose itself can trigger anaphylaxis.
• Asthma: Patients with a history of bronchial asthma are at a significantly higher risk of experiencing severe bronchospasm (narrowing of the airways) if they have a reaction to Fluorescein.
• Cardiovascular Disease: While Fluorescein is not cardiotoxic, the stress of an allergic reaction or the vasovagal response to injection can be dangerous for patients with unstable angina, recent heart attack, or severe heart failure.
• Extravasation Risk: If the needle is not perfectly seated in the vein, the dye can leak into the surrounding tissue. Because Fluorescein has a high pH, this can cause local tissue necrosis (cell death) or thrombophlebitis (blood clots in the vein). If this happens, the injection must be stopped immediately, and cold compresses should be applied.

Before the procedure, your healthcare provider will likely check your vital signs (blood pressure, heart rate). During the injection, the clinical staff will monitor you for signs of distress. No specific long-term lab tests (like liver or kidney panels) are required because of Fluorescein, but your doctor will check your kidney function (Creatinine/GFR) beforehand if they suspect you have renal impairment to decide on the appropriate dose.

Do not drive yourself home after a Fluorescein exam. There are two reasons for this:

1. 1Mydriasis: Most angiograms require your pupils to be widely dilated with other drops (like tropicamide), making you extremely sensitive to light and blurring your vision for several hours.
2. 2Visual After-images: The bright flashes from the fundus camera can leave you with temporary 'blind spots' or 'dazzle' that makes driving dangerous.

There is no direct chemical interaction between alcohol and Fluorescein. However, alcohol can cause vasodilation and may exacerbate the nausea or dizziness sometimes associated with the procedure. It is generally advised to avoid alcohol for 24 hours after the test to allow the dye to clear your system clearly.

As a single-use diagnostic agent, there is no 'discontinuation' or tapering process. Once the exam is over, the drug naturally leaves your body. There is no risk of withdrawal syndrome.

> Important: Discuss all your medical conditions, especially asthma and previous drug allergies, with your healthcare provider before starting the Fluorescein procedure.

There are no drugs that are strictly 'contraindicated' in the sense that they create a toxic chemical reaction with Fluorescein. However, the procedure itself should be avoided in patients who have had a previous life-threatening reaction to Fluorescein sodium.

• Beta-Blockers (e.g., Propranolol, Metoprolol): This is a critical interaction. Patients taking oral or ophthalmic beta-blockers may be more likely to experience a severe anaphylactic reaction. More importantly, beta-blockers can make an allergic reaction much harder to treat because they block the effects of epinephrine (the primary treatment for anaphylaxis). If you are on a beta-blocker, your doctor may take extra precautions.
• Probenecid: This medication, used for gout, reduces the renal tubular secretion of various compounds. Taking Probenecid can slow down the excretion of Fluorescein, leading to higher blood levels and longer-lasting skin/urine discoloration.

• Other Diagnostic Dyes: Using Fluorescein in close proximity to other dyes (like Indocyanine Green) is common, but the order of administration matters. Usually, Fluorescein is given first or separate from other dyes to ensure the 'glow' of one doesn't interfere with the imaging of the other.

There are no known interactions between Fluorescein and specific foods. You do not need to fast before a Fluorescein angiogram unless specifically instructed by your doctor (some doctors prefer a light meal to reduce the chance of nausea).

There are no documented interactions with common herbal supplements like St. John's Wort or Ginkgo Biloba. However, because some supplements can affect blood pressure or heart rate, you should provide a full list of everything you take to your clinician.

This is the most significant 'interaction' for Fluorescein. Because the drug is highly fluorescent, it can interfere with laboratory tests that use fluorescence-based assays. For up to 48 hours after your injection, Fluorescein in your blood or urine may cause false results in:

• Serum Digoxin levels
• Serum Cortisol levels
• Urine Catecholamines
• Serum Quinidine
• Creatinine (in certain assays)
• Glucose (in certain assays)

If you need blood work done within two days of an eye exam, you must tell the lab technician that you received Fluorescein.

Mechanism of Interaction: The interaction is typically a 'physical interference' where the dye's light emission overlaps with the light used by the lab's diagnostic machines, leading to an overestimation or underestimation of the substance being measured.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are scheduled for other lab tests shortly after your eye exam.

Fluorescein sodium must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity: If you have a documented history of a severe allergic reaction (anaphylaxis, angioedema, or severe hives) to Fluorescein sodium or any component of the formulation, you must not receive it. The risk of a fatal reaction upon re-exposure is high.
2. 2Intrathecal Injection: Fluorescein is for intravenous or topical use only. It must never be injected into the spinal canal (intrathecal). Reports of severe neurotoxicity, seizures, and death have occurred when this dye was mistakenly injected into the spinal fluid for certain surgical procedures.

In these cases, the healthcare provider will carefully weigh the diagnostic benefit against the potential risk:

• Severe Asthma: Due to the increased risk of bronchospasm during an allergic reaction.
• Pregnancy (First Trimester): While not strictly forbidden, most doctors avoid elective angiography during the first three months of pregnancy to minimize any potential risk to the developing fetus.
• Recent Myocardial Infarction (Heart Attack): The stress of the procedure or a potential reaction could trigger further cardiac issues.
• Severe Renal Failure: The dye will take much longer to clear, increasing the duration of side effects and potential toxicity.

There is no established cross-sensitivity between Fluorescein and iodine-based contrast dyes (used in CT scans). Many patients believe that if they are allergic to 'dye' in a CT scan, they will be allergic to Fluorescein. This is a myth; the chemicals are entirely different. However, a general history of severe drug allergies should always be treated with caution.

> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before deciding if Fluorescein is safe for you.

Fluorescein is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and there are no adequate, well-controlled studies in pregnant women. Fluorescein is known to cross the placental barrier and can be detected in the fetus after intravenous administration to the mother. While there is no definitive evidence of teratogenicity (birth defects), clinical practice guidelines generally recommend avoiding Fluorescein angiography in pregnant women unless the diagnostic information is essential for preventing permanent vision loss in the mother. If an angiogram is necessary, the lowest possible dose should be used.

Fluorescein is excreted in human breast milk. Following systemic injection, the dye can be present in milk for up to 76 hours. While the amount of dye the infant would ingest is small, the potential for an allergic reaction in the infant is unknown. To be safe, many experts recommend that nursing mothers express and discard their milk for 2 to 3 days (48-72 hours) after receiving an intravenous Fluorescein injection. Topical use (drops) does not require this precaution as systemic absorption is negligible.

Fluorescein is safe and effective for use in children when the dose is adjusted for body weight (7.7 mg/kg). It is frequently used in pediatric ophthalmology to diagnose congenital retinal diseases or trauma. The safety profile in children is similar to that in adults, though younger children may be more prone to fear-induced vasovagal reactions (fainting). There is no evidence that Fluorescein affects growth or development.

In patients over the age of 65, the primary concern is the higher prevalence of underlying chronic conditions. Reduced renal clearance is common in the elderly, which means the yellowing of the skin and urine may last longer (up to 48-72 hours). Additionally, elderly patients are more likely to be taking beta-blockers for hypertension or heart disease, which increases the risk and complexity of treating an allergic reaction. No specific age-based dose reduction is required, but clinical monitoring should be vigilant.

For patients with a GFR below 30 mL/min, the half-life of Fluorescein is significantly prolonged. While the dye is not known to be nephrotoxic (harmful to the kidneys), its slow clearance can be problematic. In patients on hemodialysis, Fluorescein is removed slowly. Doctors may choose to perform the angiogram on the day before a scheduled dialysis session to help clear the dye from the blood.

In patients with Child-Pugh Class B or C hepatic impairment, the metabolism of Fluorescein to its glucuronide metabolite may be delayed. This results in higher levels of the parent compound in the blood. While this might actually improve the quality of the angiogram (since the parent compound is more fluorescent), it may also increase the risk of nausea and other side effects. No formal dose adjustments are established, but caution is advised.

> Important: Special populations require individualized medical assessment to ensure the diagnostic benefits of Fluorescein outweigh the risks.

Fluorescein sodium is a hydroxyxanthene dye. Its primary function is based on its fluorescence. It absorbs light in the blue range of the visible spectrum, with peak excitation occurring between 465 and 490 nm. It then emits light in the yellow-green range, with peak emission between 520 and 530 nm. When injected into the bloodstream, it remains largely within the vascular compartment of the retina due to the blood-retinal barrier. However, in the choroid (the layer beneath the retina), the vessels are 'fenestrated' (leaky), allowing the dye to leak out and provide a background glow. In diseased states where the blood-retinal barrier is compromised, the dye leaks into the retinal tissue, which is captured by high-speed photography.

The onset of action is nearly instantaneous. After an antecubital IV injection, the dye reaches the retinal arteries in 7 to 14 seconds (the 'arm-to-retina' time). The peak fluorescence occurs shortly thereafter. The duration of 'useful' fluorescence for imaging is about 10 to 20 minutes, after which the concentration drops below the threshold for high-quality photography. There is no development of tolerance because the drug is not used chronically.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); <1% (Topical) |

| Protein Binding | 60% - 80% (Albumin) |

| Half-life | 23.5 minutes (Parent); 264 minutes (Metabolite) |

| Tmax | 7 - 14 seconds (Retinal circulation) |

| Metabolism | Hepatic (Glucuronidation) |

| Excretion | Renal 90%; Fecal <10% |

• Molecular Formula: C20H10Na2O5
• Molecular Weight: 376.27 g/mol
• Solubility: Highly soluble in water; slightly soluble in alcohol.
• Structure: It consists of three fused rings (xanthene) with an attached phenyl ring, modified with sodium salt groups to enhance water solubility.

Fluorescein is a member of the Diagnostic Dye class. Related agents include Indocyanine Green (used for deeper choroidal imaging) and Rose Bengal or Lissamine Green (used topically to stain dead or devitalized cells on the eye surface). Unlike Indocyanine Green, which is 98% protein-bound and excreted by the liver, Fluorescein is less protein-bound and excreted by the kidneys.